Siebert W, Meitinger C
Geburtshilfe Frauenheilkd. 1975 Feb;35(2):130-3.
A controlled trial of antepartum glucocorticoid treatment for prevention of respiratory distress syndrome in premature infants was carried out. 37 mothers, in whom premature delivery threatened between 28 and 37 weeks of gestation, were given intramuscular injections 8-12 mg of betamethasone as well as medication inhibiting uterine activity and strict bedrest to delay premature delivery for at least 24 to 48 hours. In comparison with a control group of 16 mothers, who received tocolytic and sedative medication and were on strict bedrest and another control group of 42 untreated patients, there was no difference in the 3 groups concerning the incidence of respiratory distress syndrome in premature infants, but there was a lower perinatal mortality rate of respiratory distress syndrome in the betamethasone treated group, than in the controls, possibly due to a milder course of respiratory distress syndrome disease by accelerating functional maturation of the fetal lung with betamethasone.
开展了一项关于产前使用糖皮质激素预防早产儿呼吸窘迫综合征的对照试验。37名妊娠28至37周有早产风险的母亲，接受了8至12毫克倍他米松的肌肉注射，同时使用抑制子宫活动的药物并严格卧床休息，以将早产推迟至少24至48小时。与16名接受宫缩抑制剂和镇静药物治疗且严格卧床休息的母亲组成的对照组，以及42名未接受治疗的患者组成的另一对照组相比，三组早产儿呼吸窘迫综合征的发生率没有差异，但倍他米松治疗组呼吸窘迫综合征的围产期死亡率低于对照组，这可能是因为倍他米松加速了胎儿肺的功能成熟，使呼吸窘迫综合征的病程较轻。
